Recent developments in Scribe Therapeutics' IPO process, including its July 2026 S-1 filing and pricing terms of $13–$15 per share targeting roughly $100 million in proceeds, have created balanced trader sentiment across market-cap buckets and the no-IPO outcome. Eli Lilly backing, a clinical pipeline focused on lipid-lowering gene therapies, and approximately $50 million in cash as of March 2026 support a post-offering valuation near $230 million, yet broader biotech IPO volatility, potential underwriter adjustments, and resolution timing before September 2026 introduce meaningful uncertainty. Market-implied odds reflect competing views on first-day closing levels relative to comparable cardiovascular and gene-editing debuts, with upcoming pricing this week serving as the immediate catalyst that could clarify the path.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено$145 млн+ 52%
$100M-$115M 47%
130–145 млн долларов 47%
Нет IPO до сентября 2026 года 42%
НОВОЕ
НОВОЕ
24 июл. 2026 г.
<85 млн долларов
28%
85–100 млн долларов
34%
$100M-$115M
47%
$115 млн - $130 млн
42%
130–145 млн долларов
47%
$145 млн+
52%
Нет IPO до сентября 2026 года
42%
$145 млн+ 52%
$100M-$115M 47%
130–145 млн долларов 47%
Нет IPO до сентября 2026 года 42%
НОВОЕ
НОВОЕ
24 июл. 2026 г.
<85 млн долларов
$0 Объем
28%
85–100 млн долларов
$0 Объем
34%
$100M-$115M
$0 Объем
47%
$115 млн - $130 млн
$0 Объем
42%
130–145 млн долларов
$0 Объем
47%
$145 млн+
$0 Объем
52%
Нет IPO до сентября 2026 года
$0 Объем
42%
This market will resolve based on Scribe Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent developments in Scribe Therapeutics' IPO process, including its July 2026 S-1 filing and pricing terms of $13–$15 per share targeting roughly $100 million in proceeds, have created balanced trader sentiment across market-cap buckets and the no-IPO outcome. Eli Lilly backing, a clinical pipeline focused on lipid-lowering gene therapies, and approximately $50 million in cash as of March 2026 support a post-offering valuation near $230 million, yet broader biotech IPO volatility, potential underwriter adjustments, and resolution timing before September 2026 introduce meaningful uncertainty. Market-implied odds reflect competing views on first-day closing levels relative to comparable cardiovascular and gene-editing debuts, with upcoming pricing this week serving as the immediate catalyst that could clarify the path.
This market will resolve based on Scribe Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Открытие рынка: Jul 21, 2026, 6:41 PM ET
Объем
$0Дата окончания
24 июл. 2026 г.Открытие рынка
Jul 21, 2026, 6:41 PM ETResolver
0x69c47De9D...This market will resolve based on Scribe Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent developments in Scribe Therapeutics' IPO process, including its July 2026 S-1 filing and pricing terms of $13–$15 per share targeting roughly $100 million in proceeds, have created balanced trader sentiment across market-cap buckets and the no-IPO outcome. Eli Lilly backing, a clinical pipeline focused on lipid-lowering gene therapies, and approximately $50 million in cash as of March 2026 support a post-offering valuation near $230 million, yet broader biotech IPO volatility, potential underwriter adjustments, and resolution timing before September 2026 introduce meaningful uncertainty. Market-implied odds reflect competing views on first-day closing levels relative to comparable cardiovascular and gene-editing debuts, with upcoming pricing this week serving as the immediate catalyst that could clarify the path.
This market will resolve based on Scribe Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Объем
$0Дата окончания
24 июл. 2026 г.Открытие рынка
Jul 21, 2026, 6:41 PM ETResolver
0x69c47De9D...Recent developments in Scribe Therapeutics' IPO process, including its July 2026 S-1 filing and pricing terms of $13–$15 per share targeting roughly $100 million in proceeds, have created balanced trader sentiment across market-cap buckets and the no-IPO outcome. Eli Lilly backing, a clinical pipeline focused on lipid-lowering gene therapies, and approximately $50 million in cash as of March 2026 support a post-offering valuation near $230 million, yet broader biotech IPO volatility, potential underwriter adjustments, and resolution timing before September 2026 introduce meaningful uncertainty. Market-implied odds reflect competing views on first-day closing levels relative to comparable cardiovascular and gene-editing debuts, with upcoming pricing this week serving as the immediate catalyst that could clarify the path.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоСвязанные
Будет ли рыночная капитализация Tarsier Pharma находиться в диапазоне от 400 до 450 миллионов долларов на момент закрытия рынка в день IPO?
40%
Да
Будет ли рыночная капитализация Reformation ниже $800 млн на момент закрытия рынка в день IPO?
47%
Да
Будет ли рыночная капитализация Jersey Mike's Subs находиться в диапазоне от $8 млрд до $9,5 млрд на момент закрытия торгов в день IPO?
32%
Да
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы